<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118193</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO16-WEH/BIORESA</org_study_id>
    <nct_id>NCT03118193</nct_id>
  </id_info>
  <brief_title>Biomarkers of Antidepressant Resistance</brief_title>
  <acronym>BIORESA</acronym>
  <official_title>Biomarkers of Antidepressant Resistance - BIORESA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the WHO, major depressive disorders have become the second worldwide cause of
      disability. Treatment, long-term medication, leads to frequent resistance (up to 40%).

      Establishing a cerebral molecular signature of depression is not feasible in humans (need for
      cerebral samples). The alternative is to use peripheral biological samples (blood, urine,
      saliva).

      Metabolomic is the integrated and quantitative study of all the metabolites of a biological
      system. This aims to define the metabolic status of an organism for a particular condition.

      Metabolites are derived from biological extracts (cells, tissues, serum, plasma, urine, etc.)
      and are detected by:

        -  liquid or gas chromatography coupled to mass spectrometry (LC-MS, GC-MS),

        -  proton nuclear magnetic resonance (1 H-NMR). The biomarkers resulting from these studies
           have become important diagnostic criteria, measured objectively and evaluated as
           indicators of a normal or pathological state, or even predictors of treatment efficacy.

      This approach allows the discovery of biomarkers that best describe the status of a disease
      for better understanding and are usable in a context of individualized medicine, with effects
      on clinical practice and management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>metabolic print of blood</measure>
    <time_frame>2 months</time_frame>
    <description>Metabolome of blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>olfactive identification</measure>
    <time_frame>2 months</time_frame>
    <description>Olfactive response: odor identification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>olfactive discrimination</measure>
    <time_frame>2 months</time_frame>
    <description>Olfactive response: odor discrimination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Olfactory threshold</measure>
    <time_frame>2 months</time_frame>
    <description>Olfactive response: olfactory threshold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiote of faeces</measure>
    <time_frame>2 months</time_frame>
    <description>Bacteria of faeces</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal measures of brain pulsatility</measure>
    <time_frame>2 months</time_frame>
    <description>Maximal brain pulsatility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean measures of brain pulsatility</measure>
    <time_frame>2 months</time_frame>
    <description>Mean brain pulsatility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic print of faces</measure>
    <time_frame>2 months</time_frame>
    <description>Metabolome of faeces</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Depressive patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>olfactive tests</intervention_name>
    <description>olfactive tests: odor identification, odor discrimination and olfactory threshold</description>
    <arm_group_label>Depressive patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood test</intervention_name>
    <description>one sample of 4mL</description>
    <arm_group_label>Depressive patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Collection of faeces</intervention_name>
    <description>Collection of faeces by patient at home - optional</description>
    <arm_group_label>Depressive patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tissue Pulsatility imaging</intervention_name>
    <description>Ultrasound exploration of brain pulsatility - optional</description>
    <arm_group_label>Depressive patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  between 18-60 years-old

          -  major depressive disorder, confirmed by Mini International Neuropsychiatric Interview
             (MINI)

          -  no bipolar disorder or schizophrenia, confirmed by MINI

          -  no neurological dementia disease

          -  able to perform olfactive tests, i.e. no anosmia and/or allergy to odors

          -  score MADRS (Montgomery AsbergDepression Rating Scale) &gt;20

          -  no antidepressant treatment during 14 days before inclusion

          -  informed written consent

          -  affiliation to a social security system

        Exclusion Criteria:

          -  patient who don't want any antidepressant treatment for this depressive episode

          -  legal incapacity and/or any circumstances making the person unable to understand the
             trial features, purposes or consequences

          -  participating to drug clinical study or in exclusion period of clinical study because
             of previous participation

          -  pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wissam El-Hage, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU TOURS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wissam El-Hage, PhD</last_name>
    <phone>02 47 47 37 28</phone>
    <email>wissam.elhage@univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wissam El-Hage, PhD</last_name>
      <email>wissam.elhage@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Wissam El-Hage, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu Lemaire, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Baptiste Courtine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Camus, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Desmidt, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Val√©rie Gissot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>antidepressant</keyword>
  <keyword>resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

